Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial

By D. Gonzales, S. Rennard, M. Nides, C. Oncken, S. Azoulay, C. Billing, Watsky Eric Jacob, J. Gong, K. Williams, K. Reeves. 2006

1,248 citations recorded by the source corpus.

Subfields: Molecular Biology, Neurology, Physiology

View Paper: https://www.semanticscholar.org/paper/a9e2b476632ed44b8838275e7ed922f2e7ca0a4e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. A. Garcia-Romeu
2. Roland R. Griffiths
3. Matthew W. Johnson
4. Mary P Cosimano

In Physiology

1. A. Garcia-Romeu
2. Roland R. Griffiths
3. Matthew W. Johnson
4. Mary P Cosimano

Citations in the corpus

• Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction (2014, background): “For example, when paired with 12 brief weekly counseling meetings, pharmacotherapies have shown seven-day point prevalence abstinence rates of 24.9% to 26.3% (bupropion) and 33.5% to 35.2% (varenicline) at approximately 6 months post-TQD (Gonzales et al., 2006; Jorenby et al., 2006).”